rss
Thorax 2007;62:690-695 doi:10.1136/thx.2006.069872
  • Lung cancer

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

  1. Pietro Bertino1,
  2. Camillo Porta2,
  3. Dario Barbone1,
  4. Serena Germano1,
  5. Sara Busacca1,
  6. Sabrina Pinato1,
  7. Giancarlo Tassi3,
  8. Roberto Favoni4,
  9. Giovanni Gaudino1,
  10. Luciano Mutti5
  1. 1DISCAFF Department and DFB Center, University of Piemonte Orientale “A Avogadro”, Novara, Italy
  2. 2Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy
  3. 3Chest Medicine Unit, Brescia Hospital, Brescia, Italy
  4. 4National Cancer Institute, Genoa, Italy
  5. 5Local Health Unit, 11 Piemonte, Italy
  1. Correspondence to:
    Dr Giovanni Gaudino
    DISCAFF Department and DFBC Center, University of Piemonte Orientale“A Avogadro”, 28100 Novara, Italy; giovanni.gaudino{at}unipmn.it
  • Received 3 August 2006
  • Accepted 19 January 2007
  • Published Online First 20 February 2007

Abstract

Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma.

Methods: Cultures from mesothelioma MMP, REN and ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent.

Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRβ positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed.

Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.

Footnotes

  • Published Online First 22 February 2007

  • GG and LM contributed equally to the study.

  • This work was supported by research grants to GG from AIRC (Associazione Italiana per la Ricerca sul Cancro), MARF (Mesothelioma Applied Research Foundation) and the Buzzi Foundation (Casale Monferrato, Italy). This work is part of G.I.Me. (Gruppo Italiano per lo Studio e la Terapia del Mesotelioma) network program.

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. web only appendices
  5. All Versions of this Article:
    1. thx.2006.069872v1
    2. thx.2006.069872v2
    3. 62/8/690 most recent

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Thorax.
View free sample issue >>

Free archive
The full back archive is now available for Thorax. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.